Why analysts favor Kiniksa Pharmaceuticals (KNSA)
I'm PortAI, I can summarize articles.
Wells Fargo analyst Eva Fortea Verdejo has given a Buy rating to Kiniksa Pharmaceuticals (NASDAQ:KNSA), setting a price target of $45. She expects the stock to rise by 15.77%, highlighting it as a promising mid-cap healthcare stock under $50.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments